

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy
Policy No:	PCN 177 -2015
Date of Issue	November 2015
Review Date:	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p>Recommendations: The PCN supports the use of Vedolizumab for treating moderately to severely active Crohn's Disease after prior therapy.</p> <p>Prescribing would be by hospital specialists only, in line with NICE TA352 using the Blueteq initiation and continuation forms. Vedolizumab will be considered RED on the traffic light system</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> NICE TA352 – Vedolizumab for treating moderately to severely active Crohn's Disease after prior therapy. http://www.nice.org.uk/guidance/ta352/resources/vedolizumab-for-treatingmoderately-to-severely-active-crohns-disease-after-prior-therapy82602664948933 	
Date taken to Area Prescribing Committee	November 2015
Agreed by APC members	November 2015